12/23/2025
Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) and its Collaborators Expand Clear Cell Ovarian Cancer Trial https://bit.ly/493v4az
–Plans to double the Number of Patients in Study– –Company Expects Initial Findings to be presented in 2026– December 23, 2025 (Source) — LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a biotech company focused on advancing cancer treatments, today an...